For “neurological diseases”, the use of adrenergic uptake inhibitors, traditionally used as antidepressants, was the top repurposing candidate; for “diabetes”, alpha 1 antagonists and kinase inhibitors were identified as possible novel treatments (Table 3). Here, PSMA6 is linked to nervous system disorder.